MM-120-101
33 evidence topics · 7 sources
Objective
Comparison of the phase 2b capsule with the phase 3 orally disintegrating tablet
Purpose of the bridging study stated in the annual report
Location and study date
Registry record
| Item | Registry record |
|---|---|
| Scientific title | “Phase I trial: MM-120-101” |
| IRAS number | “1007602” |
| Sponsor | “Mind Medicine Inc” |
| Countries of recruitment | “United Kingdom” |
| Participating centre | “MAC Clinical Research Liverpool” |
| Participating centre | “MAC Clinical Research Manchester” |
| Date of first enrolment | “13/10/2023” |
| Date of final enrolment | “04/12/2023” |
| Completion date | “19/12/2023” |
| Overall study status | “Deferred” |
Ethics approval
| Item | Research summary |
|---|---|
| REC name | “Wales REC 1” |
| REC reference | “23/WA/0112” |
| Date of REC opinion | “1 Sep 2023” |
| REC opinion | “Further Information Favourable Opinion” |
Deferred publication of registry details
Study design
Open-label, randomized, two-period crossover design
Study schedule
| Period | Quoted study day |
|---|---|
| Screening | “-21 to -1” |
| Washout | “2-13” |
| Follow-up | “15-29” |
Registry design description
| Item | Registry record |
|---|---|
| Study design | “Phase 1 study in 30 healthy volunteers” |
| Primary study design | “Other” |
| Phase | “Phase I” |
| Intervention type | “Drug” |
Assessments: plasma pharmacokinetics, subjective effects, and adverse events
Eligibility criteria
Entry criteria
| Criterion | Quoted entry criterion |
|---|---|
| Sex | “Men and Women” |
| Age | “Ages 18-55” |
| Health status | “Healthy volunteers” |
| Medications | “No prohibited medications” |
Registry eligibility fields
| Item | Registry record |
|---|---|
| Participant type | “Healthy volunteer” |
| Age group | “Adult” |
| Sex | “All” |
| Health condition studied | “Healthy volunteers” |
Treatment
Four 25 µg capsules and one 100 µg orally disintegrating tablet, in randomized sequence
Formulations named in the study schematic
Study outcomes
Rationale for using plasma pharmacokinetic parameters as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size
| Item | Registry record |
|---|---|
| Target sample size at registration | “30” |
Description of analysis sets
Analysis methods
Safety analysis set in the pooled safety analysis
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetic comparison: abstract results
Geometric mean ratios relative to the capsule
| Parameter | Quoted geometric mean ratio |
|---|---|
| Cmax | “GMR: 1.02” |
| AUC0-∞ | “GMR: 1.17” |
Company-derived comparisons and their bases, March 2024
“50% faster onset of action” (opens the source at this quote in a new tab)
“17% improved bioavailability” (opens the source at this quote in a new tab)
“23% increase in AUC at target conc.” (opens the source at this quote in a new tab)
“Reduced GI side effects” (opens the source at this quote in a new tab)
Health-related quality of life and patient-reported outcomes
Subjective drug effects on visual analogue scales
Safety results
Treatment-emergent adverse events by formulation: abstract
Treatment-emergent adverse events in the pooled safety poster
| Measure | Phase 1 PK bioavailability study, DT120 ODT (n = 29) |
|---|---|
| Any TEAE | “25 (86.2)” |
| Mild | “15 (51.7)” |
| Moderate | “9 (31.0)” |
| Severe | “1 (3.4)” |
Serious adverse events, suicidality, and vital signs across the four pooled studies
Study limitations
Summary
MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.
Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.
Risk stated by the company from the change in formulation
Formulation bridging named as a condition for adoption
“Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote